Loading...
XASE
CHRO
Market cap7mUSD
Jun 06, Last price  
1.14USD
1D
6.02%
1Q
-47.72%
IPO
-76.26%
Name

Chromocell Therapeutics Corp

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
199,9340000
Net income
-8m
L+7.78%
-660,584-595,387-2,458,589-7,380,793-7,955,338
CFO
-6m
L+490.45%
-3,625,773-1,593,011-1,567,149-981,031-5,792,483

Profile

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
IPO date
Feb 16, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
7,571
9,442
2,710
Unusual Expense (Income)
NOPBT
(7,571)
(9,442)
(2,710)
NOPBT Margin
Operating Taxes
(690)
Tax Rate
NOPAT
(7,571)
(9,442)
(2,019)
Net income
(7,955)
7.78%
(7,381)
200.20%
(2,459)
312.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,888
255
BB yield
-164.78%
Debt
Debt current
1,269
540
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(513)
1,172
485
Cash flow
Cash from operating activities
(5,792)
(981)
(1,567)
CAPEX
1
Cash from investing activities
Cash from financing activities
6,210
1,022
1,622
FCF
(10,033)
(7,432)
(1,434)
Balance
Cash
513
96
55
Long term investments
Excess cash
513
96
55
Stockholders' equity
(21,474)
(13,520)
(6,138)
Invested Capital
18,760
8,344
2,972
ROIC
ROCE
278.97%
182.42%
85.59%
EV
Common stock shares outstanding
5,574
5,768
5,768
Price
0.64
 
Market cap
3,573
 
EV
3,060
EBITDA
(6,879)
(9,254)
(2,710)
EV/EBITDA
Interest
786
519
140
Interest/NOPBT